You are here
Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer
WATERTOWN, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the promotion of Larry Edwards, Chief Commercial Officer, to Chief Operating Officer. In his new role as COO Larry will also continue to oversee all aspects of pre-commercialization activities for eravacycline in complicated intra-abdominal infections (cIAI).
“Larry is a natural leader and the best candidate for the role of Tetraphase’s Chief Operating Officer, with his expertise in commercializing and marketing antibiotics and a solid track record of leadership within the company,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “As we continue to prepare for the potential commercialization of our lead candidate, eravacycline in cIAI, Larry’s guidance in both the pre-commercial activities, as well as overseeing operations, will be essential in ensuring that we are poised for a strong commercial launch in the U.S. and Europe in the second half of the year, assuming regulatory approvals.”
“I am thrilled to be taking on this new leadership role at Tetraphase,” said Larry Edwards. “We believe there is significant opportunity for eravacycline in cIAI, and I look forward to continuing to work with the rest of management to prepare to commercialize eravacycline as a new treatment option for patients suffering from these serious, and often life-threatening, MDR gram-negative infections.”
Larry Edwards joined Tetraphase in 2015 as Vice President of Marketing, became Vice President of Commercial Operations in 2016, and was appointed Chief Commercial Officer in the beginning of 2017. Prior to joining Tetraphase, Mr. Edwards served as Senior Director of Marketing, Gram Negative Franchise, with Cubist Pharmaceuticals, Inc. (later acquired by Merck), where he was responsible for all pre-launch or post-launch marketing activities for ZERBAXA. Prior to his work at Cubist, he was Global Marketing Director, Clostridium Difficile & New Infectious Disease Products, with Merck & Co., where he led all pre-launch marketing activities for early and late stage hospital infectious disease products. Mr. Edwards received a Bachelor of Science in Business & Healthcare Administration from Ohio University.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the MDR bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in cIAI by the U.S. Food and Drug Administration(FDA) and the European Medicines Agency (EMA), and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the FDA or the respective foreign regulatory agencies; whether, if any clinical candidate obtains such approval, it will be successfully distributed and marketed by the Company or its licensees; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 1, 2017. In addition, the forward-looking statements included in this press release represent our views as of March 1, 2018. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
Sam Brown Inc.